Whats your number
Mantle Cell
CD5, FMC7, CD43
CD10- CD23-
t(11;14) --> cyclinD1
R/R DLBCL treatment <12 mos
Bridging therapy
Axi cel
Lisa cel
Tisa Cel
CD19
RICE!
Burkitt Lymphoma IPI
Age ≥40 years
ECOG performance status ≥2
LDH >3× upper limit of normal
CNS involvement
High Risk = >2 factors
Brentuximab vedotin
ADC CD30
PML!! Neuropathy Rash Cytopenias
Lymphoma workup
LP
Echo
EBV, HCV, HBV, HIV, CMV, HTLV-1 (Why?) LDH, SPEP
PET
LP
Anaplastic T Cell Lymphoma
CD30+
CD2, CD3, CD5, CD7 negative
+/- ALK
R/R >12 mos
R-ICE
R-DHAP
R-GDP
Methotrexate
Cytarabine
Thiotepa
Rituximab
Glofitamab
CD3 CD20
CRS
Cytopenias
IPI
Age >60
LDH >wnl
ECOG >2
Ann Arbor III/IV (What is it?)
EN >1
NGC DLBCL
CD 10+ CD20+ CD19+ CD79a often BCL6- MUM1
nfkb activation!!!
R/R DLBCL non transplant eligible
tafasitamab + lenalidomide
Pola + BR
Selinexor (12% response rate)
Anaplastic T Cell Lymphoma treatment
BV-CHP x6
Loncastuximab
ADC CD19
Hyperglycemia, peripheral edema, rash
HIV associated Lymphoma
r-epoch
Burkitts
CD10+, CD19+, CD20+, BCL6+
cMYC dysregulation t(8;22)
3rd line therapy
Loncastuximab adc
Epcoritamab
Glofitamab
Low risk Burkitts treatment
3 cycles of DA-EPOCH-RR (with double-dose rituximab on days 1 and 5) if PET-negative after 2 cycles
6 cycles of DA-EPOCH-R if PET-positive after initial 2 cycles
Neuropathy + Cytopenias
Testicular Lymphoma treatment
Orchiectomy + XRT to contralateral testes
PMBCL
CD19 CD20 weak CD30
PD-1
R/R PMBCL
axi cel
Liso cel
Pembro
High Risk Burkitts treatment
6 cycles of DA-EPOCH-R plus intrathecal methotrexate
CART
CD19 + 2 internal signaling domains CD3, CD28
CRS
Cytopenias
B cell aplasia
hypogammaglobulinemia
Loss of CD19
BMBx, US Testicular, Slit Lamp, total spine mr